A Phase II, Single-Arm, Open-Label Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2017
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Genentech
- 31 Aug 2018 Biomarkers information updated
- 22 Dec 2011 Actual patient number is 110 according to ClinicalTrials.gov.
- 22 Dec 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.